Longtime cancer R&D chief Peter Lebowitz is taking his final bows at J&J oncology. Now what?
As the head of Johnson & Johnson’s oncology R&D, Peter Lebowitz’s portfolio ran the scientific gamut, from discovery through development and on to the big combos and post-approval studies that grow major drug franchises in the cancer arena.
The sheer scope of his career, running more than 11 years as oncology chief, put him in the driver’s seat for a range of big drugs like Darzalex, a fast-growing multiple myeloma blockbuster which underpins the entire commercial aspirations of a global pharma giant that is doubling down on its pipeline as the engine of revenue growth.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.